Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: NDAC September meetings

This article was originally published in The Tan Sheet

Executive Summary

NDAC September meetings: FDA formally announces the Sept. 27-28 joint meetings of the Nonprescription Drugs Advisory Committee in the Aug. 22 Federal Register. On Sept. 27, NDAC and the Endocrinologic & Metabolic Drugs Advisory Committee will review Bristol-Myers Squibb's switch NDAs for Questran and Questran Light and discuss issues related to cholesterol-reducing treatments. On Sept. 28, NDAC meets with the Drug Abuse Advisory Committee to discuss SmithKline Beecham's Nicorette (2 mg and 4 mg) and with the Gastrointestinal Drugs Advisory Committee to review Whitehall-Robins' NDA for nizatidine 75 mg ("The Tan Sheet" Aug. 21, pp 1-4). Both meetings begin at 8:30 a.m. in Conference Rooms D & E of FDA's Parklawn Building. On Sept. 29, NDAC will attend a public hearing on OTC labeling reform. A closed session is scheduled for 5-6 p.m. on Sept. 27 with the endocrine committee...

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS084231

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel